1. Home
  2. CION vs RLMD Comparison

CION vs RLMD Comparison

Compare CION & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CION

CION Investment Corporation

HOLD

Current Price

$7.12

Market Cap

344.9M

Sector

Finance

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$7.33

Market Cap

319.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CION
RLMD
Founded
2011
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
344.9M
319.7M
IPO Year
2011
2012

Fundamental Metrics

Financial Performance
Metric
CION
RLMD
Price
$7.12
$7.33
Analyst Decision
Sell
Strong Buy
Analyst Count
1
5
Target Price
$7.00
$12.40
AVG Volume (30 Days)
657.5K
1.3M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
16.95%
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.55
N/A
Revenue Growth
N/A
154.83
52 Week Low
$6.50
$0.27
52 Week High
$10.93
$7.94

Technical Indicators

Market Signals
Indicator
CION
RLMD
Relative Strength Index (RSI) 47.01 63.77
Support Level $6.55 $3.49
Resistance Level $7.27 $7.41
Average True Range (ATR) 0.23 0.44
MACD 0.09 0.01
Stochastic Oscillator 69.13 73.01

Price Performance

Historical Comparison
CION
RLMD

About CION CION Investment Corporation

CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Companies portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Share on Social Networks: